Janus Kinase (JAK) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2017

  • ID: 4330885
  • Drug Pipelines
  • 323 pages
  • DelveInsight
until Dec 31st 2018
1 of 3
“Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017” provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Janus Kinase (JAK) Inhibitors. This report provides information on the therapeutic development based on Janus Kinase (JAK) Inhibitors mechanism of action dealing with around 35+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. The report also assesses the Janus Kinase (JAK) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 25+ active companies involved in the therapeutic development of the products.

  • The report provides competitive pipeline landscape of Janus Kinase (JAK) Inhibitors
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Janus Kinase (JAK) Inhibitors
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Janus Kinase (JAK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Janus Kinase (JAK) Inhibitors and also provide company profiling
  • The report also gives the information of dormant pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Reasons to Buy:
  • Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
  • Complete MOA intelligence and complete understanding over therapeutics development for Janus Kinase (JAK) Inhibitors
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Devise corrective measures for pipeline projects by understanding Janus Kinase (JAK) Inhibitors pipeline depth and focus of Indication therapeutics
  • Developing strategic initiatives to support your drug development activities.
  • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
  • Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
  • Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Note: Delivery of this report takes up to 24 hours after purchase.
Note: Product cover images may vary from those shown
2 of 3
  1. Introduction
  2. Executive Summary
  3. Executive Summary Snapshot
  4. Janus kinase Inhibitors (JAK Inhibitors) Overview
  5. Introduction
  6. Structure and Mechanism
  7. Janus Kinase Inhibitors
  8. Types of JAK Inhibitors
  9. Cytokines associated with Janus kinases and result of their mutations
  10. JAK Inhibitors Market Analysis
  11. Collaborations and Deals
  12. Acquisition Deals
  13. Designations Analysis
  14. Grants
  15. Financing
  16. Companies Involved in JAK Inhibitor Development
  17. Therapeutic Targets by Company and Indication
  18. Market Drivers and Barriers
  19. Drivers
  20. Barriers
  21. Marketed Products
  22. Therapeutics under Development by Companies
  23. Late Stage Products (Filed &Phase III)
  24. Comparative Analysis
  25. Mid Stage Products (Phase II)
  26. Comparative Analysis
  27. Early Stage Products (Phase Iand IND)
  28. Comparative Analysis
  29. Discovery and Pre-clinical stage Products
  30. Comparative Analysis
  31. Therapeutic Assessment
  32. Assessment by Monotherapy Products
  33. Assessment by Route of Administration
  34. Assessment by Stage and Route of Administration
  35. Assessment by Molecule Type
  36. Assessment by Stage and Molecule Type
  37. Dormant Products
  38. Companies involved in Therapeutics Development
  39. Upcoming Conferences
  40. SWOT Analysis for JAK Inhibitors
  41. Appendix
  42. Methodology
  43. Consulting Services
  44. About Us
  45. Contact Us
  46. Disclaimer
List of Tables
Table 1: Collaboration and Deal Values for JAK Inhibitors, 2017
Table 2: Acquisition deals for the development of JAK Inhibitors, 2017
Table 3: Grants, 2017
Table 4: Number of Products Under Development for Janus Kinase (JAK) Inhibitors, 2017
Table 5: Number of Products under Development by Companies, 2017
Table 6: Late Stage Products (Filed &Phase III), 2017
Table 7: Mid Stage Products (Phase II), 2017
Table 8: Early Stage Products (Phase Iand IND), 2017
Table 9: Discovery and Pre-clinical stage Products, 2017
Table 10: Assessment by Monotherapy Products, 2017
Table 11: Assessment by Route Of Administration, 2017
Table 12: Assessment by Stage and Route Of Administration, 2017
Table 13: Assessment by Molecule Type, 2017
Table 14: Assessment by Stage and Molecule Type, 2017
Table 15: Dormant Products, 2017
Table 16: Discontinued Products, 2017
Table 17: AbbVie, Overview, 2017
Table 18: Aclaris Therapeutics, Inc., Overview, 2017
Table 19: Advinus Therapeutics, Overview, 2017
Table 20: Amgen Inc., Overview, 2017
Table 21: Aptose Biosciences, Overview, 2017
Table 22: Arrien Pharmaceuticals, Overview, 2017
Table 23: Asana BioSciences, Overview, 2017
Table 24: Astellas Pharma Inc., Overview, 2017
Table 25: Astrazeneca, Overview, 2017
Table 26: Bristol-Myers Squibb, Overview, 2017
Table 27: CleveXel Pharma, Overview, 2017
Table 28: Cloud pharmaceuticals, Overview, 2017
Table 29: Concert Pharmaceuticals, Overview, 2017
Table 30: CTI BioPharma, Overview, 2017
Table 31: Cytopia Research, Overview, 2017
Table 32: Eli Lilly and Company, Overview, 2017
Table 33: Galapagos NV, Overview, 2017
Table 34: Gilead Sciences, Overview, 2017
Table 35: Hoffmann-La Roche, Overview, 2017
Table 36: Incyte Corporation, Overview, 2017
Table 37: Japan Tobacco Company, Overview, 2017
Table 38: Nimbus Therapeutics, Overview, 2017
Table 39: Pfizer Inc., Overview, 2017
Table 40: Portola Pharmaceuticals, Overview, 2017
Table 41: Sareum Limited, Overview, 2017
Table 42: Theravance Biopharma, Overview, 2017
Table 43: Tragara Pharmaceuticals, Overview, 2017
Table 44: Vectura Group, Overview, 2017

List of Figures
Figure 1: Structure of Janus Kinase
Figure 2: Illustrated mechanism of Janus Kinase
Figure 3: Collaboration and Deals for JAK Inhibitors, 2017
Figure 4: Number of Companies under acquisition for JAK Inhibitors, 2017
Figure 5: Designation Analysis for JAK Inhibitors, 2017
Figure 6: Grants, 2017
Figure 7: Number of Products under Development for JAK Inhibitor, 2017
Figure 8: Number of Products under Development for Janus Kinase(JAK) Inhibitors, 2017
Figure 9: Late Stage Products (Filed &Phase III), 2017
Figure 10: Mid Stage Products (Phase II), 2017
Figure 11: Early Stage Products (Phase Iand IND ), 2017
Figure 12: Discovery and Pre-clinical stage Products, 2017
Figure 13: Number of Products under Development forJAK Inhibitors, 2017
Figure 14: Assessment by Route of Administration, 2017
Figure 15: Assessment by Stage and Route of Administration, 2017
Figure 16: Assessment by Molecule Type, 2017
Figure 17: Assessment by Stage and Molecule Type, 2017
Figure 18: Dormant Products, 2017
Figure 19: Discontinued Products, 2017
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown